Skip to main content

GenoMax3.1, GenomePixelizer, Readseq


Bethesda, Md.-based InforMax has released GenoMax 3.1, which contains two new modules: the GenoMax Protein-Protein Interaction Analysis module and the GenoMax Genome Analysis module.

The Protein-Protein Interaction module was developed in conjunction with AxCell Biosciences. It allows research scientists to access and correlate the protein pathway information in AxCell''s ProChart database of human protein interactions with other data. The first ProChart release describes over 69,000 unique domain-ligand interactions. GenoMax customers and ProChart subscribers will have access to the data generated by AxCell''s ongoing efforts to map all of the protein interactions in the human body.

The Genome Analysis module for chromosome and EST mapping enables clustering, analysis, and assembly of genomic sequences and features a collection of tools for navigation, management, and viewing of genomic data.

Additional enhancements to GenoMax include expanded automation of research protocols and refinement of the graphical user interface.

A team at the University of California Davis department of vegetable crops has developed GenomePixelizer comparative genomics software, which is now available at

GenomePixelizer generates custom images of genomes out of a given set of genes. Each element on the picture has a physical address defined by coordinates.

The program is written in Tcl/Tk and works on any platform that supports the Tcl/Tk toolkit. Source code is freely available.

Don Gilbert of the bioinformatics group at Indiana University has released the latest version of his Readseq bioinformatics conversion program, which reads and writes nucleic acid and protein sequences in various formats. It is available at readseq/java/.

The new release includes a graphic user interface and a common gateway interface.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.